
Drug treatment
HealthNew drug combination stops prostate cancer growth in phase 3 clinical trial
Adding niraparib to standard prostate cancer therapy delays disease progression by nearly 50% in men with BRCA mutations.
Mac Oliveau

Adding niraparib to standard prostate cancer therapy delays disease progression by nearly 50% in men with BRCA mutations.
Mac Oliveau